CD274 and cancer: Since increasing evidence is revealing that the overexpression of tumor-associated PD-L1 is a weak and insufficient predictive biomarker of therapy response in different cancer populations, the identification of solid predictors is an urgent and challenging clinical need, to optimize treatment selection [16].